Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Shareholders Approve US IPO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A majority of Osmetech's shareholders have approved the firm's plans to proceed with an initial public offering and other proposals, according to a notice posted on the London Stock Exchange.

Last month, Osmetech said that it had filed with the US Securities and Exchange Commission for the IPO under the name of its newly proposed parent, GenMark Diagnostics.

At the time, the maker of microarray-based molecular diagnostics said that its board of directors had approved the proposal, which includes reorganizing the firm so that it becomes a wholly-owned subsidiary of GenMark, based in Pasdadena, Calif. They also approved moving its shares from the AIM, on which it currently trades, to the Nasdaq Global Market, under which shareholders would receive one share of GenMark for every 230 shares of Osmetech held.

According to the notice posted on the LSE today, Osmetech's shareholders approved the plans, with only 21 percent of shareholders representing .03 percent of Osmetech's shares voting against the proposals.

A court hearing is scheduled to take place on May 20 to sanction the plans.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.